Eftilagimod Alpha
Not Tagged
['sclc', 'nsclc', 'emd']
get ready for months of the potential benefit of lag3 in nsclc impossible to judge the activity of the soluble lag-3 protein eftlagimod alpha without randomization. combined with a pd-1 blocker: no safety signal, efficacy could be only related to patients selection. #asco22 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.